An Open, Comparative Study of Sulbactam plus Ampicillin vs. Cefotaxime as Initial Therapy for Serious Soft Tissue and Bone and Joint Infections

Rational antibiotic therapy and the position of ampicillin/sulbactam

“…The clinical efficacy rates of 80-100% for AMS compared favourably with those of other antibiotics used (65-97%). AMS (9 g/day) and cefotaxime were also efficacious for serious soft-tissue and bone and joint infections, with cure or improvement observed in all 13 patients treated with the combination and in 7 of 9 patients treated with cefotaxime [51].…”

Amoxycillin-clavulanate versus methicillin or isoxazolyl penicillins for treatment of Staphylococcus aureus infections

“…Good in-vitro anti-staphylococcal activity is reflected in efficacy in vivo, as shown in the experimental model of endocarditis (Cantoni etal., 1989;Franciolli etal., 1991;Fluckigere/a/., 1992;Entenza et al, 1994) as well as clinically (Fleisher, Wilmott & Campos, 1983;Camacho et al, 1992;Powers, 1993;Tassler, 1993;Moreillon, 1994). Good results have been obtained with ampicillin/sulbactam in children with staphylococcal skeletal infections (Aronoffe/ al., 1986;Loffler et al, 1986). On the basis of such results co-amoxiclav has been used for empirical treatment of infections which might involve S. aureus (Goldstein etal., 1987;Bass etal., 1993;Moreillon, 1994).…”